Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Nilufer Avci"'
Autor:
Murat Bardakci, Hilal Karakas, Dogan Bayram, Nilufer Avci, Sait Kitapli, Mirac Ozen, Ferit Aslan, Caglar Koseoglu, Ahmet Kadioglu, Ilknur D. Onur, Teoman Sakalar, Mahmut Buyuksimsek, Ali Alkan, Yakup Ergun, Ali O. Kaya, Burak Bilgin, Bulent Yalcin
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract While some clinics have adopted abbreviated neoadjuvant treatment for HER2-positive breast cancer, there remains a shortage of comprehensive clinical data to support this practice. This is a retrospective, multicenter study. A total of 142 p
Externí odkaz:
https://doaj.org/article/026e682bc12d48feb5f956194dcd0fe4
Autor:
Ozgur Tanriverdi, Eyup Murat Yilmaz, Serkan Menekse, Suna Cokmert, Esin Oktay, Kezban Nur Pilanci, Muharrem Kocar, Nilufer Avci, Tulay Akman, Gamze Goksel, Nezih Meydan, Sabri Barutca
Publikováno v:
Journal of Oncological Sciences, Vol 2, Iss 2, Pp 48-52 (2016)
Background: This study aimed to identify the risk factors related in recurrence with isolated intra-abdominal lymph node metastasis in patients with colorectal cancer. Methods: This is a retrospective, cross-sectional study of 21 colorectal cancer pa
Externí odkaz:
https://doaj.org/article/104db83b76c4453a9e348245916787fb
Autor:
Arife Ulas, Fatma Paksoy Turkoz, Kamile Silay, Saadet Tokluoglu, Nilufer Avci, Berna Oksuzoglu, Necati Alkis
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114471 (2014)
We aimed to establish a laboratory prognostic index (LPI) in advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze the predictive value of LPI on NSCLC survival.The study retrospectively r
Externí odkaz:
https://doaj.org/article/6032908549874f0f9cf78544de607693
Autor:
Cigdem Benlice, Mehmet Ali Koc, Baris Gulcu, Ismail Ahmet Bilgin, Cihangir Akyol, Bilgi Baca, Ersin Ozturk, Yildiz Guney, Gungor Utkan, Ozlem Er, Fulya Agaoglu, Ibrahim Yildirim, Nilufer Avci, Atilla Halil Elhan, Mehmet Ayhan Kuzu
Publikováno v:
Diseases of the Colon & Rectum. 66:681-690
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4359814885aaf685a5bc04a99df5073
https://doi.org/10.1097/dcr.0000000000002646
https://doi.org/10.1097/dcr.0000000000002646
Autor:
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, Semih Akin, Fatih Yildiz, Merve Turan, Sema Sezgin Goksu, Ismail Beypinar, Teoman Sakalar, Mustafa Değirmenci, Dilek Erdem, Gul Basaran, Omer Fatih Olmez, Nilufer Avci, Deniz Tural, Abdullah Sakin, Sema Turker, Atakan Demir, Suleyman Temiz, Muhammed Ali Kaplan, Mutlu Dogan, Ozgur Tanriverdi, Irem Bilgetekin, Havva Yesil Cinkir, Ozgur Acikgoz, Semra Paydas, Ruchan Uslu, Serdar Turhal
© 2021 Taylor & Francis Group, LLC.Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc88869b3476dea5a33f45cbc1f4df24
https://hdl.handle.net/11454/77155
https://hdl.handle.net/11454/77155
Autor:
T Sakalar, Muhammet Ali Kaplan, I Bilgetekin, M Degirmenci, Ömer Fatih Ölmez, Nilufer Avci, R. Uslu, S Akin, Serkan Menekse, Ozgur Tanriverdi, D Tural, A Bilici
Publikováno v:
Cancer Research. 79:P6-18
Background: Endocrine treatment and chemotherapy are a treatment options for patients with hormone receptor (HR) positive and HER2-negative metastatic breast cancer (MBC). However, response to first-line hormone treatment could not obtained in all pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef1c67f8591f29afda58dba3c137db12
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-37
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-37
Autor:
Faysal Dane, Bulent Karabulut, Senem Karabulut, Nilufer Avci, Hasan Şenol Coşkun, Levent Korkmaz, Devrim Cabuk, Nazim Serdar Turhal, Mustafa Karaagac, Nuri Faruk Aykan, Hatice Doruk, Mehmet Artac
Publikováno v:
Surgical Oncology. 27:485-489
Purpose We aimed to investigate the prognostic effect of primary tumor resection (PTR) prior to bevacizumab-based treatments in unresectable metastatic colorectal cancer (mCRC). Methods We retrospectively collected 341 mCRC cases with unresectable me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2feda29b3737a865165ac6e6a0ffc530
https://doi.org/10.1016/j.suronc.2018.05.032
https://doi.org/10.1016/j.suronc.2018.05.032
Autor:
Hasan Şenol Coşkun, Hatice Doruk, Nazim Serdar Turhal, Mustafa Karaagac, Levent Korkmaz, Senem Karabulut, Faysal Dane, Devrim Cabuk, Mehmet Artac, Nilufer Avci, Nuri Faruk Aykan, Bulent Karabulut
Publikováno v:
Journal of Gastrointestinal Cancer. 50:214-220
The purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy. A total of 563 patients with mCRC who had received first-line chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6031b2aacb075fa9da446b5583a6c2d
https://doi.org/10.1007/s12029-017-0047-2
https://doi.org/10.1007/s12029-017-0047-2
Autor:
Tarık Şengöz, Nilufer Avci
Publikováno v:
Clinical Nuclear Medicine. 45:146-147
We describe a rare case of metastatic pilomatrix carcinoma with distant metastases 10 months after diagnosis. A 37-year-old woman was diagnosed with pilomatrix carcinoma by excisional biopsy from the occipital region and referred to us for 18F-FDG PE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::018564835fe7daf27a8c68ab183526ee
https://doi.org/10.1097/rlu.0000000000002857
https://doi.org/10.1097/rlu.0000000000002857
Autor:
Nazim Serdar Turhal, Hatice Doruk, Senem Karabulut, Faysal Dane, Devrim Cabuk, Hasan Şenol Coşkun, Bulent Karabulut, Nilufer Avci, Levent Korkmaz, Nuri Faruk Aykan, Mehmet Artac, Mustafa Karaagac
Publikováno v:
Journal of Gastrointestinal Cancer. 47:264-272
Several chemotherapy regimens using bevacizumab have been developed. Our goal was to investigate regimens that have demonstrated significant clinical activity in patients with metastatic colorectal cancer (mCRC). Six hundred and sixty six patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4558304acdef9dfc89cca685f8a0c2f9
https://doi.org/10.1007/s12029-016-9823-7
https://doi.org/10.1007/s12029-016-9823-7